Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin
<p>Abstract</p> <p>Background</p> <p>In this paper, we report the health related quality of life (HRQOL) data from patients with hepatitis C viral infection (HCV) who were refractory to prior therapy and had re-treatment with a combination of Pegylated interferon alpha-...
Main Authors: | McGarrity Thomas J, Rhoades Kathy, Peiffer Laurie P, Mathew Abraham |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2006-05-01
|
Series: | Health and Quality of Life Outcomes |
Online Access: | http://www.hqlo.com/content/4/1/30 |
Similar Items
-
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
by: Gonçales Neiva SL, et al.
Published: (2010-07-01) -
Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy
by: Eric M Yoshida, et al.
Published: (2009-01-01) -
Ischemic Colitis During Pegylated Interferon-Alpha and Ribavirin Therapy for Chronic Hepatitis C
by: Yvette Leung, et al.
Published: (2006-01-01) -
Characteristics of hepatitis C treatment with pegylated interferons and ribavirin
by: Ricardo Jiménez-Méndez, et al.
Published: (2010-01-01) -
Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C
by: Yasser K. Rashed, et al.
Published: (2020-02-01)